{"id":"formoterol-12-g-dpi","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Palpitations"},{"rate":"1-5","effect":"Muscle cramps"},{"rate":"1-5","effect":"Nervousness"},{"rate":"1-5","effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Formoterol activates beta-2 adrenergic receptors on bronchial smooth muscle, triggering increased intracellular cAMP levels that lead to smooth muscle relaxation and sustained bronchodilation. The 12 µg dry powder inhaler (DPI) formulation provides rapid onset and long-acting bronchodilatory effects, typically lasting 12 hours, making it suitable for maintenance therapy in obstructive airway diseases.","oneSentence":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:59.005Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT07372573","phase":"NA","title":"Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler","status":"NOT_YET_RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2026-02-01","conditions":"Asthma (Diagnosis)","enrollment":210},{"nctId":"NCT07133880","phase":"PHASE4","title":"Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators","status":"RECRUITING","sponsor":"University of Tennessee Graduate School of Medicine","startDate":"2023-12-05","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":72},{"nctId":"NCT00476099","phase":"PHASE3","title":"Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2006-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":828},{"nctId":"NCT01191424","phase":"PHASE2","title":"A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients.","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-10","conditions":"Asthma","enrollment":57},{"nctId":"NCT02291016","phase":"NA","title":"COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers","status":"COMPLETED","sponsor":"University of Tennessee Graduate School of Medicine","startDate":"2015-02","conditions":"COPD Exacerbation","enrollment":7},{"nctId":"NCT00862394","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-02","conditions":"Asthma","enrollment":783},{"nctId":"NCT00972140","phase":"PHASE3","title":"Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2005-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":457}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Formoterol 12 µg DPI","genericName":"Formoterol 12 µg DPI","companyName":"Chiesi Farmaceutici S.p.A.","companyId":"chiesi-farmaceutici-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}